Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Trial Profile

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs CAEL 101 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Nov 2018 According to a Caelum Biosciences media release, data will be presented at the 60th American Society of Hematology (ASH) Annual Meeting.
    • 25 Jun 2018 According to a Caelum Biosciences media release, data from the phase 1b part of the study were presented at the American Society of Echocardiography (ASE) 29th Annual Scientific Sessions.
    • 18 Jun 2018 According to a Caelum Biosciences media release, data from the phase 1b part of the study will be presented at the American Society of Echocardiography (ASE) 29th Annual Scientific Sessions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top